Table 1 Characteristics of studies included in meta-analysis.

From: The clinical effect of nicorandil on perioperative myocardial protection in patients undergoing elective PCI: A Systematic Review and Meta-Analysis

Author year country Sample number Average age (years) Use method of Nicorandil (dose) preoperative method of Control group outcome Measures
N C C N
XM Ceng21 2015 china 100 100 59.4 ± 10.2 59.4 ± 10.2 Venous pump (12 mg/day) Conventional therapy CK-MB,TnT
WN Pei22 2014 china 40 32 56.97 ± 9.83 56.97 ± 9.83 Oral (15 mg/day) Conventional therapy CK-MB,TnT
JZ Lv23 2015 china 25 20 55.41 ± 9.82 55.13 ± 9.62 Oral (15 mg/day) Conventional therapy CK-MB,TnT
FR Mo24 2016 china 26 31 60.35 ± 12.45 61. 37 ± 10. 98 Oral (15–30 mg/day) Conventional therapy TnT
XP Wu25 2013 china 48 44 61.3 ± 8.4 61.3 ± 8.4 Oral (15 mg/day) Conventional therapy CK-MB,TnT
YH Li26 2012 china 52 48 66.4 ± 10.2 64.8 ± 10.5 Oral (15 mg/day) Conventional therapy CK-MB,TnT
Y Zhang27 2012 china 30 30 61.0 ± 5.8 63.0 ± 6.2 Oral (15 mg/day) Conventional therapy CK-MB,TnT
HY Han28 2015 china 45 49 58.64 ± 8.53 56.93 ± 9.74 Oral (15 mg/day) Conventional therapy CK-MB,TnT
SH Yang29 2014 china 37 38 65.37 ± 8.24 64.27 ± 8.66 Oral (15 mg/day) Conventional therapy CK-MB,TnT
XC Wang30 2012 china 42 48 63.47 ± 9.24 63.37 ± 8.06 Oral (15 mg/day) Conventional therapy CK-MB,TnT
Shehata M20 2014 Egypt 50 50 59.4 ± 7.4 60.2 ± 4.3 Oral (20 mg/day) Conventional therapy CK-MB,TnT
Murakami M19 2006 Japan 91 101 65.0 ± 9.7 66.1 ± 10.3 intravenous (2 μg/kg/min) Conventional therapy CK-MB,TnT
Kim S18 2012 Korea 54 55 65.5 ± 7.4 63.2 ± 9.2 Intracoronary (4 mg) Conventional therapy CK-MB,TnT
Isono T31 2008 Japan 23 26 66.3 ± 7.9 66.5 ± 9.4 intravenous (6 mg/h for 24 h) Conventional therapy CK-MB,TnT
Kim J17 2005 korea 100 100 60.4 ± 11.7 61.7 ± 8.2 Intravenous (10–15 mg/day) Conventional therapy CK-MB,TnT
Hwang J16 2013 Japan 41 40 66.2 ± 9 65.3 ± 10 Intracoronary (4 mg) Conventional therapy CK-MB,TnT
  1. N: Nicorandil group, C: control group.